|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
AT1R (rs 5182) CT genotype is mildly associated with STEMI (OR = 1.1), but also prone to have PCI after ACS attack (OR = 1.6) while TT genotype has a risk to get less improvement (OR = 1.8).
|
31195108 |
2020 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Randomized controlled trials (RCT) comparing a loading dose of atorvastatin to a control in patients with ACS who underwent PCI were identified through searches of medical literature databases.
|
30608526 |
2019 |
|
SERPINA5
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
For this purpose 571 consecutive ACS patients receiving ticagrelor (n = 258, 45%) or prasugrel (n = 313, 55%) undergoing PCI were enrolled in this prospective, observational, multicenter ATLANTIS-SWITCH substudy.
|
31160687 |
2019 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 56.1% patients underwent PCI for acute coronary syndrome (ACS).
|
30826192 |
2019 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
The study population consisted of the consecutive patients who underwent PCI with the Magmaris BRS in the settings of ACS.
|
30537203 |
2019 |
|
SERPINA5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The RENAMI project is a multicenter retrospective observational registry enrolling 4424 patients with ACS treated with PCI and prasugrel or ticagrelor plus aspirin.
|
30228021 |
2018 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
The main goal of Statins Evaluation in Coronary procedUres and REvascularization (SECURE-PCI) Trial is to determine whether the early use of a loading dose of 80 mg of atorvastatin before an intended percutaneous coronary intervention followed by an additional dose of 80 mg 24 hours after the procedure will be able to reduce the rates of major cardiovascular events at 30 days in patients with an ACS.
|
29653634 |
2018 |
|
SERPINA5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
<b>Methods:</b> In 582 consecutive patients with stable coronary artery disease (CAD) or acute coronary syndrome (ACS) scheduled for PCI and treated with ASA and Clopidogrel, Prasugrel, or Ticagrelor, SNP analysis for rs12566888, rs2768759, rs41273215, rs3737224, and rs822442 was performed.
|
29867494 |
2018 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
As a result, the majority of patients undergoing PCI shifted from stable angina pectoris (SA) to acute coronary syndrome (ACS).
|
28992998 |
2018 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
In ACS patients with LM disease, revascularization with PCI is feasible and safe, with short-term outcomes comparable to ACS patients without significant LM disease.
|
29493510 |
2018 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thirty-two patients who underwent PCI using the Filtrap® for acute coronary syndrome (ACS) were enrolled.
|
29915959 |
2018 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the indication of 1 year DAPT after coronary angioplasty for ACS has been supported by an outdated randomized trial (PCI-CURE).
|
29776573 |
2018 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prolonging DAPT more than 12 months after PCI for ACS only associated with a lower risk of ischemic events in the 1-4 years after PCI in those receiving first generation DES.
|
27860195 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Between January and June 2015, 808 patients with ACS undergoing PCI were considered for further analysis.
|
28632784 |
2017 |
|
SERPINA5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The CRUSADE and ACTION scores had a greater calibration and discrimination for in-hospital major bleeding compared with the ACUITY-HORIZONS score in Chinese patients with ACS undergoing PCI.
|
28491083 |
2017 |